After a long stretch of regulatory hassles, Vikas Dandekar of PharmAsiaNews.Com believes the worst is behind for the pharma major with this USFDA boost, a USD 3.4 billion opportunity.
Ranbaxy Labs has managed an approval from the US Food and Drug Administration (USFDA) to launch the first generic version of Swiss drugmaker Novartis' Diovan (Valsartan) in the US market, for which it enjoys a 180 days exclusive marketing rights.
After a long stretch of regulatory hassles, Vikas Dandekar of PharmAsiaNews.Com believes the worst is behind for the pharma major with this USFDA boost, a USD 3.4 billion opportunity.
However, according to him, Active Pharmaceutical Ingredient (API) sourcing will be done from third party.
With USFDA approval for Valsartan drug , confidence has risen on pending approvals for Nexium and Valcyte drugs. Although sourcing alliance for Nexium generic seems to be in place, a similar deal could be witnessed, he says in an interview with CNBC-TV18's Sonia Shenoy and Reema Tendulkar.
Transcript to be added shortly
Ranbaxy Labs stock price
On June 27, 2014, at 09:24 hrs Ranbaxy Laboratories was quoting at Rs 498.15, up Rs 26.40, or 5.60 percent. The 52-week high of the share was Rs 510.45 and the 52-week low was Rs 253.95.
The latest book value of the company is Rs 3.41 per share. At current value, the price-to-book value of the company was 146.09.
Anda sedang membaca artikel tentang
USFDA boost for Ranbaxy; see akin deal for Nexium: Dandekar
Dengan url
http://sehatkafein.blogspot.com/2014/06/usfda-boost-for-ranbaxy-see-akin-deal.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
USFDA boost for Ranbaxy; see akin deal for Nexium: Dandekar
namun jangan lupa untuk meletakkan link
USFDA boost for Ranbaxy; see akin deal for Nexium: Dandekar
sebagai sumbernya
0 komentar:
Posting Komentar